PARISI, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 276
EU - Europa 205
AS - Asia 119
AF - Africa 34
OC - Oceania 1
Totale 635
Nazione #
US - Stati Uniti d'America 275
SE - Svezia 58
IT - Italia 45
CN - Cina 32
SG - Singapore 32
DE - Germania 26
VN - Vietnam 24
GB - Regno Unito 22
IE - Irlanda 21
IN - India 21
TG - Togo 15
BG - Bulgaria 10
CI - Costa d'Avorio 10
JO - Giordania 9
NG - Nigeria 9
CH - Svizzera 8
NL - Olanda 5
ES - Italia 2
FI - Finlandia 2
FR - Francia 2
UA - Ucraina 2
AU - Australia 1
CA - Canada 1
PL - Polonia 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 635
Città #
Ashburn 34
Fairfield 27
Chandler 26
Singapore 25
Woodbridge 25
Dong Ket 24
Southend 22
Dublin 21
Lomé 15
Princeton 14
Houston 12
Bologna 11
Abidjan 10
Cambridge 10
Sofia 10
Wilmington 10
Abeokuta 9
Amman 9
Seattle 9
Beijing 8
Turin 8
Bern 6
Hyderabad 6
Santa Clara 6
Redmond 5
Berlin 3
Des Moines 3
Haltern 3
Jinan 3
Milan 3
Moncalieri 3
Borgomanero 2
Breda 2
Cesena 2
Ferrara 2
Florence 2
Helsinki 2
Medford 2
Naaldwijk 2
New York 2
Palermo 2
S. Pietro 2
San Diego 2
Tarragona 2
Tianjin 2
Westminster 2
Xi'an 2
Ann Arbor 1
Boydton 1
Bremen 1
Buffalo 1
Bühl 1
Carlentini 1
Collegeville 1
Den Haag 1
Guangzhou 1
Hangzhou 1
Imola 1
Istanbul 1
Los Angeles 1
Melbourne 1
Mülheim 1
Phoenix 1
Redwood City 1
Rome 1
Shanghai 1
Taicang 1
Toronto 1
Venezia 1
Warsaw 1
Wuhan 1
Totale 436
Nome #
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 129
PO.8 COELIAC DISEASE MISDIAGNOSIS IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY 100
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 77
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 74
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 63
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 52
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 47
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 45
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 41
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 29
Totale 657
Categoria #
all - tutte 2.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.491


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202031 0 0 0 0 0 0 0 9 10 5 5 2
2020/2021122 6 3 2 1 32 18 0 8 11 5 4 32
2021/2022134 0 3 5 3 14 6 2 22 7 7 48 17
2022/2023233 14 25 18 12 25 23 4 10 57 8 20 17
2023/202469 9 5 0 8 3 25 0 9 0 1 8 1
2024/202568 21 26 17 4 0 0 0 0 0 0 0 0
Totale 657